Vicapsys Life Sciences appoints Federico Pier as CEO, effective Feb 15, 2022

Vicapsys Life Sciences, Inc.

Federico Pier appointed CEO effective Feb 15, 2022; previously interim CEO since Aug 2020 and Executive Chairman since May 2019.
Pier has 25+ years of experience in reverse mergers, structured finance, convertible debt, and equity; past roles at Oppenheimer & Co. and Bear Stearns.
Company develops VICAPSYN for transplantation and VYBRIN for post-surgical adhesions; trades OTC under symbol VICP.
The appointment was announced via press release dated April 12, 2022.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Federico Pier

Chief Executive Officer

VICP · Vicapsys Life Sciences, Inc.

Effective: 2022-02-15
Filed: April 12, 2022, 7:59 PM ET

On February 15, 2022, the Board of Directors (the “Board”) of Vicapsys Life Sciences, Inc. (the “Company”) appointed Federico Pier as Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Federico Pier was appointed as Chief Executive Officer at Vicapsys Life Sciences, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On February 15, 2022, the Board of Directors (the “Board”) of Vicapsys Life Sciences, Inc. (the “Company”) appointed Federico Pier as Chief Executive Officer of the Company.

View on SEC.gov

Vicapsys Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-009690

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.